GCTK · Glucotrack, Inc. · Executive Compensation
$1.14
-0.07 (-5.79%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based upon this review and our current financial condition, we have concluded that substantial doubt exists as to our ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$1.28M
Shares
705,255
Volume · Oct 2
301.42K
Avg daily vol (24 sessions)
3.59M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Peter Wulff | CFO | $500,000 |
| Peter C. Wulff | Former Chief Financial Officer | $500,000 |
| Paul V. Goode | Former Chief Executive Officer | $394,100 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Paul V. Goode | Former Chief Executive Officer | $352,096 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Paul V. Goode | Chief Executive Officer | $356,237 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Paul Goode | Chief Executive Officer | $485,685 |
| James Thrower | Chief Technology Officer | $361,362 |
| Jolie Kahn | Chief Financial Officer | $120,000 |
| Erez Ben Zvi | General Manager and VP of Product (resigned June 26, 2022) | $110,245 |
| Shalom Shushan | Chief Technology Officer (resigned May 22, 2022) | $109,108 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Jolie Kahn | Chief Financial Officer | $120,000 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| David Podwalski | Former President | $240,683 |
| Eugene Naidis | Vice President of R&D | $192,587 |
| David Malka | President | $174,235 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| David Malka | President | $402,268 |
| David Podwalski | Former President | $392,093 |
| Eugene Naidis | Vice President of R&D | $291,453 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Paul V. Goode | Board | Resigned | 2026-09-18 |
| Paul Goode | chief executive officer of the Operating Sub | Appointed | 2026-07-15 |
| Erik Emerson | member of the Acquiror Board of Directors | Appointed | 2026-07-15 |
| Erik Emerson | Chief Executive Officer | Appointed | 2026-07-15 |
| Peter C. Wulff | Chief Financial Officer | Appointed | 2025-01-29 |
| James Cardwell | Chief Financial Officer | Resigned | 2025-01-29 |
| John Ballantyne | board member | Appointed | 2024-09-03 |
| Paul V. Goode | board member | Appointed | 2024-09-03 |
| Andrew Sycoff | board of directors | Resigned | 2024-07-31 |
| Shimon Rapp | board of directors | Resigned | 2024-07-31 |
| Andrew K. Balo | independent board member | Appointed | 2024-06-20 |
| James S Cardwell | Chief Financial Officer | Appointed | 2023-10-12 |
| Jolie Kahn | Chief Financial Officer | Resigned | 2023-10-12 |
| Erin Carter | director | Appointed | 2023-08-31 |